The Business Research Company’s Glucagon-like Peptide 1 Global Market Report 2023 is the most detailed report available on the market, including broad forecast periods and multiple geographies. The report covers the historic period – 2010-2021, and the forecast period – 2023-2032. The Glucagon-like Peptide 1 Global Market Report 2023 evaluates glucagon-like peptide 1 market size, growth rate, drivers, trends, and major companies.
The report provides a global perspective by covering 60 geographies and focusing on major economies in each region – Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Request A Free Sample Of The Report (Includes Graphs And Tables):
https://www.thebusinessresearchcompany.com/sample.aspx?id=10830&type=smp
The global glucagon-like peptide 1 market size is expected to grow from $18.11 billion in 2022 to $19.51 billion in 2023 at a compound annual growth rate (CAGR) of 7.8%. The Russia-Ukraine war disrupted the chances of global economic recovery from the COVID-19 pandemic, at least in the short term. The war between these two countries has led to economic sanctions on multiple countries, a surge in commodity prices, and supply chain disruptions, causing inflation across goods and services and affecting many markets across the globe. The global glucagon-like peptide 1 market size is expected to reach $25.89 billion in 2027 at a CAGR of 7.3%.
The glucagon-like peptide 1 market segments in the report are:
1) By Product: Trulicity, Ozempic, Victoza, Rybelsus, Other Types
2) By Route of Administration: Oral, Parenteral, Other Routes
3) By End-Users: Hospitals, Specialty Clinics, Other End Users
Get More Information On The Glucagon-like Peptide 1 Market Report:
https://www.thebusinessresearchcompany.com/report/glucagon-like-peptide-1-global-market-report
The table of contents in TBRC’s glucagon-like peptide 1 market report includes:
1. Executive Summary
2. Glucagon-like Peptide 1 Market Characteristics
3. Glucagon-like Peptide 1 Market Trends And Strategies
4. Glucagon-like Peptide 1 Market - Macro Economic Scenario
5. Glucagon-like Peptide 1 Market Size And Growth
…..
26. Africa Glucagon-like Peptide 1 Market
27. Glucagon-like Peptide 1 Market Competitive Landscape And Company Profiles
28. Key Mergers And Acquisitions In The Glucagon-like Peptide 1 Market
29. Glucagon-like Peptide 1 Market Future Outlook and Potential Analysis
30. Appendix
Learn About Us:
The Business Research Company is a market intelligence firm that pioneers in market, company, and consumer research, with 6500+ reports. TBRC’s specialist consultants are located globally and are experts in a wide range of industries that include healthcare, manufacturing, financial services, chemicals, and technology. The firm has offices located in the UK, the US, and India, along with a network of proficient researchers in 28 countries.
Recent Reports:
https://www.openpr.com/news/3157837/binders-and-scaffolders-for-meat-and-meat-substitutes-market
https://www.openpr.com/news/3156516/global-agriculture-sprayers-market-2023-regional-overview
https://topprnews.com/care-management-solutions-market-report/
https://topprnews.com/broadcast-communications-equipment-market-report/
https://topprnews.com/global-genetically-modified-crops-market-share/
Contact Us:
The Business Research Company
Europe: +44 207 1930 708
Asia: +91 88972 63534
Americas: +1 315 623 0293
Email: [email protected]
Follow Us On:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
Twitter: https://twitter.com/tbrc_info
Facebook: https://www.facebook.com/TheBusinessResearchCompany
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Blog: https://blog.tbrc.info/
Healthcare Blog: https://healthcareresearchreports.com/
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
As indicated by the International Diabetes Federation in 2019, around 463 million people developed 20 - 79 years were surveyed to be diabetic throughout the planet.
Additionally, overweight and heavy people are given the threats of making diabetes and cardiovascular disorders.
Imaginative items are being created which are relied upon to speed up the development of the market for GLP-1 receptor agonist.
Drug organizations are making advancements as far as plans, improved bioavailability, blend treatments, and course of the organization.
For example, in September 2019, Novo Nordisk presented Rybelsus in the U.S. Glucagon-Like Peptide-1 (Glp-1) Analogs Market.
It is the first once-week after-week oral semaglutide based tablet and has been discovered to be more viable than customary treatment choices for the decrease of HbA1C and mean difference in body weight in the clinical investigations.
